Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Dr Hagensee on Strategies For Cervical Cancer Prevention

February 14th 2024

Michael Hagensee, MD, PhD, discusses strategies for cervical cancer prevention and ongoing research investigating barriers to cervical cancer treatment.

Phase 3 Randomized Trials: Expanding Clinically Meaningful Analysis Beyond the Stated Goals

February 9th 2024

The foundation of physician recommendations and medical/regulatory policy will be guided by the outcomes of published clinical research.

Complementary NGS Improves dMMR Detection With IHC in CRC and Endometrial Cancer

February 8th 2024

Amin Nassar, MD, and Elias Bou Farhat, MD, spotlight a study evaluating the accuracy and sensitivity of NGS mutation signature in assessing MMR status vs IHC testing.

Future Perspectives on HER2 ADCs in Gynecological Cancer

February 8th 2024

Martin Dietrich, MD, PhD, and Ritu Salani, MD, share their outlook on the future roles of HER2-directed ADCs in gynecological cancers and other solid tumors, highlighting the necessity for additional research to provide further understanding in these areas.

Expert Insights on HER2 Testing in Gynecological Cancers

February 8th 2024

Ritu Salani, MD, provides expert insights regarding HER2 testing in patients with gynecological cancers, emphasizing the need for standardization in testing practices and greater clarity surrounding the incidence of HER2 positivity across gynecological cancers.

EMA Validates MAA for Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer

February 2nd 2024

The MAA seeking the approval of tisotumab vedotin in select patients with recurrent or metastatic cervical cancer has been validated by the EMA.

HER2 ADCs in Cervical Cancer: A Promising Therapeutic Frontier

February 1st 2024

Ritu Salani, MD, highlights impactful findings from the DESTINY-PanTumor02 study in patients with cervical cancer, highlighting the promising role of HER2-directed ADCS in this treatment space.

HER2 ADCs in Endometrial Cancer: Shaping the Treatment Landscape

February 1st 2024

Ritu Salani, MD, discusses impactful efficacy signals from T-DXd in the DESTINY-PanTumor02 study for endometrial cancer, marking a potential breakthrough in this treatment field.

Dr Salani on the De-Escalation of Therapy in Gynecologic Oncology

January 29th 2024

Ritu Salani, MD, discusses the de-escalation of therapy and unmet needs within the landscape of gynecologic oncology.

Onvansertib Induces Preclinical Anti-Tumorigenic Effects in Endometrioid Endometrial Cancer

January 27th 2024

Nikita Sinha, MD, discusses the effects of onvansertib on cellular proliferation, adhesion, apoptosis, and stress in endometrial cancer cells.

SGO Winter Meeting Spotlights Key Developments and Debates Across Gynecologic Oncology

January 26th 2024

Ritu Salani, MD, provides an overview of the variety of sessions presented at the 2024 SGO Winter Meeting.

Dr. Sinha on the Antitumor Effects of Onvansertib in a Preclinical Endometroid Endometrial Cancer Model

January 26th 2024

Nikita Sinha, MD, discusses the potential effects of onvansertib on endometroid endometrial cancer pathogenesis in a preclinical model.

Preclinical Study Reveals Potential Role for GLP Agonists in Endometrial Cancer

January 26th 2024

Danielle Krause, MD, discusses preclinical findings from mouse models evaluating GLP-1 agonists with and without progesterone in endometrial cancer.

Toxicities From Lenvatinib/Pembrolizumab Associated With Treatment Response in Gynecologic Malignancies

January 26th 2024

Paulina J. Haight, MD, discusses the association between the occurrence of toxicities with response to treatment with lenvatinib and pembrolizumab.

Dr Krause on GLP-1 Receptor Agonist Therapy in Endometrial Cancer

January 26th 2024

Danielle Krause, MD, discusses the effects of GLP-1 receptor agonist therapy in endometrial cancer.

Dr Haight on Predictors of Treatment Toxicity in Gynecologic Malignancies

January 26th 2024

Paulina J Haight, MD, discusses predictors of toxicity and treatment response with lenvatinib and pembrolizumab in patients with gynecologic malignancies.

Emerging Data for HER2 ADCs in Ovarian Cancer

January 25th 2024

Ritu Salani, MD, presents an outline of the treatment landscape for ovarian cancer and underscores encouraging data from the DESTINY-PanTumor02 study, showcasing promising results in this treatment setting.

Landscape Surrounding HER2 ADCs in GI Cancers

January 25th 2024

Martin Dietrich, MD, PhD, discusses the role of HER2 ADCs in GI cancers, reviewing key data from DESTINY-Gastric and DESTINY-CRC trials.

The Role of Genetics in Cancer Care Continues to Expand

January 18th 2024

Genetic screening and testing have only recently become an integral part of cancer care.

Targeting HER2 Alterations with ADCs in NSCLC

January 18th 2024

Martin Dietrich, MD, PhD, examines the safety and efficacy of HER2-directed ADCs in NSCLC, emphasizing significant differences in response associated with HER alterations.